Celldex Therapeutics, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. Celldex is a clinical-stage biopharmaceutical company developing immunotherapies and antibody-drug conjugates, with lead programs in glioblastoma, breast cancer, and other cancers. The filing is unaudited; amounts below are in millions of dollars unless otherwise indicated.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $2.433 | $2.516; down 3% |
| Research and development expense | $10.769 | $6.853; up 57% |
| Operating loss | $(13.288) | $(9.658) |
| Net loss | $(13.516) | $(10.059); loss increased 34% |
| Net loss per share | $(0.27) | $(0.31) |
| Net cash used in operating activities | $(13.553) | $(8.864) |
- Product royalties were $2.344 million, down 6%; development/licensing revenue was $35,000 and contracts/grants revenue was $54,000. Royalty revenue is matched by royalty expense, so it contributed no corresponding operating margin.
- Gross margin is not presented as a meaningful measure for this development-stage business. Total operating expense was $15.721 million, versus revenue of $2.433 million.
- At March 31, cash and cash equivalents were $22.755 million and marketable securities were $69.374 million, totaling $92.129 million. Working capital was $81.7 million. Management said available funds should support planned operations for at least 12 months.
- Term-loan carrying value was approximately $15.2 million. The loan carries interest at the greater of LIBOR plus 6.25% or 9.50%; principal installments began April 1, 2012, and the amended maturity is December 2014. The debt is secured by substantially all assets other than intellectual property. Celldex reported compliance with its covenants.
- Financing activities provided $51.914 million, principally from $43.4 million net proceeds from an underwritten offering and $8.5 million from its controlled equity offering. Shares outstanding increased from 44.211 million at year-end to 58.736 million at March 31.
Material changes and operating developments
- The net loss increase was primarily attributable to higher R&D spending. Product development costs rose $3.615 million, mainly due to the ACT IV and ReACT rindopepimut trials. Management expected operating cash use and trial spending to increase, particularly for rindopepimut.
- Rindopepimut was in a pivotal randomized Phase 3 study (ACT IV) and a Phase 2 recurrent-disease study (ReACT). Celldex estimated ACT IV would cost more than $50 million to complete; targeted enrollment was 24 months, followed by 18–24 months of follow-up.
- CDX-011’s Phase 2b breast-cancer study had completed enrollment. The FDA placed it on partial clinical hold after manufacturing-practice violations were identified at a contract manufacturer. Existing patients could continue under specified conditions; the FDA also agreed in concept to crossover using an older lot, subject to restrictions. Reprocessing the affected lot was not assured, and failure to obtain usable supply could delay a subsequent trial.
- Celldex amended its term-loan agreement in March, extending maturity from December 2013 to December 2014 and incurring a $25,000 upfront fee plus a $37,500 final payment fee.
- Rotarix royalties were subject to a 30% license fee payable to Cincinnati Children’s Hospital. The relevant patent was scheduled to expire in December 2012; a third-party royalty-sharing agreement was also scheduled to end then unless extended.
Outlook, risks, and contingencies
- Management stated that current liquidity was sufficient for at least the next 12 months, but said it might seek additional capital for longer-term needs. Additional financing was not assured and could dilute shareholders, impose debt obligations or covenants, or reduce product economics through licensing terms. Failure to raise funds could force program or trial delays, early licensing, unfavorable financing, or a sale of some or all of the business.
- Management expected CDX-011 topline Phase 2b results in Q2 2012 and mature data in Q4 2012; preliminary ReACT data in mid-2013; CDX-1127 Phase 1 enrollment completion by year-end 2012; CDX-1401 data in the second half of 2012; and a CDX-1135 Phase 2 pilot study to begin in the second half of 2012. These are expectations, not assurances.
- Key risks include clinical-trial safety and efficacy, regulatory approval, trial cost and enrollment timing, manufacturing and clinical-service availability, competition, intellectual-property validity and litigation, and dependence on partners. Early-stage results may not predict later-stage outcomes; rindopepimut results cited against historical controls were not a substitute for the ongoing controlled Phase 3 study.
- Celldex reported no material changes to the risk factors in its 2011 Form 10-K. It also reported no material changes in internal control over financial reporting and concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Actual quarterly and subsequent cash burn against the 12-month liquidity estimate, and whether additional capital or partnerships are needed.
- ACT IV enrollment, cost, conduct, and results; and progress and results of the other clinical programs.
- FDA decisions on the CDX-011 partial hold, reprocessing and supply availability, and any effect on future development.
- Terms and timing of debt principal payments, fees, and covenant compliance following the loan amendment.
- Rotarix royalty receipts and the effect of the December 2012 patent and royalty-sharing agreement milestones.